Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 8, 2013, Pages 1617-1619

  Blondon, M ^a,b   Wiggins, K L ^a   Harrington, L B ^a   Psaty, B M ^a,c   Smith, N L ^a,c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c CENTER FOR HEALTH STUDIES   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; CONJUGATED ESTROGEN; CYTOCHROME P450 3A5; ESTROGEN; NUCLEAR FACTOR; NUCLEAR FACTOR (ERYTHROID DERIVED 2) LIKE 2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN MODIFICATION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS;

ABO BLOOD-GROUP SYSTEM; ADMINISTRATION, ORAL; AGED; ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENETIC VARIATION; HORMONES; HUMANS; MIDDLE AGED; NF-E2-RELATED FACTOR 2; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PULMONARY EMBOLISM; REGRESSION ANALYSIS; RISK FACTORS; VENOUS THROMBOSIS; WASHINGTON;

EID: 84881580948     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12309     Document Type: Article

References (7)

1. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR, Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-80.
2. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves GK, The Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012; 10: 2277-86.
3. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006; 96: 1226-35.
4. Bouligand J, Cabaret O, Canonico M, Verstuyft C, Dubert L, Becquemont L, Guiochon-Mantel A, Scarabin PY, Estrogen and Thromboembolism Risk (ESTHER) Study Group. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther 2011; 89: 60-4.
5. Canonico M, Bouaziz E, Carcaillon L, Verstuyft C, Guiochon-Mantel A, Becquemont L, Scarabin P-Y, Estrogen and Thromboembolism Risk (ESTHER) Study Group. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 2008; 93: 3082-7.
6. Canonico M, Olié V, Carcaillon L, Tubert-Bitter P, Scarabin P-Y, Estrogen and Thromboembolism Risk (ESTHER) Study Group. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: the ESTHER study. Thromb Haemost 2008; 99: 246-8.
7. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292: 1581-7.